Navigation Links
Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
Date:10/18/2007

SAN MARINO, Calif., Oct. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA. On October 22, 2007 at 8:00 a.m., Dr. Hall will present the scientific principles, the clinical validation, and global development status of the company's innovative pathotropic (disease-seeking) -- targeting technology embodied in its lead product, Rexin-G, the first pathotropically targeted genetic medicine developed for the treatment of advanced-stage and metastatic cancer.

(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

The Global Pharma R&D Summit 2007 (http://www.globalpharmasummit.com), which will be held at the Boston Marriott Hotel, Newton MA 02466 USA, on October 22-23, 2007, showcases cutting-edge biotechnology and pharmaceutical companies that are developing superior technologies and products in healthcare and healthcare related areas, and offers a forum to meet with suppliers, service providers, opinion leaders, and representatives from other leading pharmaceutical and biotechnology companies worldwide. The Keynote Address provides an opportunity for Epeius to update the industry in regard to its recent clinical developments and global partnering initiatives to expedite the international development of Rexin-G, which is currently in clinical trials in Europe, Japan, and ASEAN member countries, as well as the United States.

The focus on Epeius Biotechnologies during National Breast Cancer Awareness Month, is apropos-for the company has just opened an Advanced Phase I/II trial for chemo-resistant breast cancer in San Marino and Santa Monica California. Rexin-G, has received Orphan Drug Status from the FDA based on unprecedented demonstrations of single-agent efficacy in treating pancreatic cancer. Subsequently, the company has gained federal support and private agency support to continue their landmark clinical trials in the United States using intravenous Rexin-G for breast cancer that afflicts one of 4 women and sarcoma that afflicts teen-agers and young adults. These Phase I/II clinical trials with adaptive trial designs will facilitate the development of Rexin-G for breast cancer, sarcoma and pancreatic cancer in the United States.

In addition to leading the advancement of bioscience and medicine from "the bench to the bedside" in a manner that is unprecedented in modern times, Dr. Hall and the senior management team of Epeius Biotechnologies continues to raise the bar for the biopharmaceutical industry in terms of corporate productivity, R&D efficiency, and significant drug development. Having (i) gained exclusive licensing rights for all of the tumor targeting and molecular-genetic technologies embodied in Rexin-G, (ii) conducted international clinical trials that validated the lead product, (iii) advanced the yield of biopharmaceutical GMP through a series of major technological innovations, (iv) attained both Orphan Drug Status and Expanded Access Designation through various regulatory authorities, (v) generated the company's first million dollars in revenues through product sales, and (vi) initiated a bold corporate outreach program that facilitated the development of strategic alliances and corporate partnering, Dr. Hall's invited Keynote Address at the Global Pharma R&D Summit will be a tough act to follow.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries -- thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for partnership or clinical trials, please visit us at http://www.epeiusbiotech.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System
3. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
4. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
5. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
7. Performance of fluorescent dyes with LEADseeker Multimodality Imaging System
8. Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System
9. Use of BRET2 luminescence cell-based assays with LEADseeker Multimodality Imaging System
10. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
11. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand ... a flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. ... suited where extreme precision is required, such as in medical equipment, laboratory instrumentation, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):